Loading...
Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
The antisense oligonucleotide Nusinersen has been recently licensed to treat spinal muscular atrophy (SMA). Since SMA type 3 is characterized by variable phenotype and milder progression, biomarkers of early treatment response are urgently needed. We investigated the cerebrospinal fluid (CSF) concen...
Na minha lista:
| Udgivet i: | J Cell Mol Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7077557/ https://ncbi.nlm.nih.gov/pubmed/32032473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14939 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|